| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -127,130 | -93,783 |
| Depreciation and amortization | 232 | 152 |
| Accrued financing on prepaid forward obligation | 1,595 | 123 |
| Accretion on marketable securities | 1,800 | 1,640 |
| Share-based compensation | 8,829 | 5,802 |
| Amortization (accretion) of discount on long-term debt | 377 | 774 |
| Amortization of right of use assets | 1,500 | 941 |
| Acquisitions of ipr&d | 3,128 | 3,128 |
| Inventory | -886 | -2,099 |
| Accounts receivable, net | -599 | -653 |
| Prepaid expenses and other current assets | 3,277 | 3,210 |
| Other non-current assets | 6,170 | 212 |
| Accounts payable and accrued expenses | -1,258 | 3,531 |
| Employee related accrued expenses | 544 | 1,076 |
| Other current liabilities | -201 | 62 |
| Lease liabilities | -1,972 | -1,344 |
| Restricted deposit | -1 | -1 |
| Net cash used in operating activities | -124,119 | -81,849 |
| Purchases of marketable securities | 76,861 | 68,140 |
| Maturities of marketable securities | 110,974 | 70,768 |
| Purchases of property and equipment | 272 | 185 |
| Net cash provided by investing activities | 33,841 | 2,443 |
| Proceeds from exercise of options into ordinary shares | 629 | 327 |
| Proceeds from issuance of long-term debt | 0 | - |
| Proceeds from pre-funded warrant issuance, net of issuance costs | 3 | 3 |
| Proceeds from ordinary shares issuances, net of issuance costs | 7,970 | 0 |
| Net cash provided by financing activities | 8,602 | 330 |
| Increase (decrease) in cash and cash equivalents | -81,676 | -79,076 |
| Cash and cash equivalents at beginning of period | 173,062 | - |
| Cash and cash equivalents at end of period | 91,386 | - |
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)